FDA Releases Final Guidance for Special Protocol Assessments

The FDA finalized guidance on its special protocol assessment (SPA) program that offers sponsors an advanced declaration from the agency that their trial designs, clinical endpoints, and statistical analyses are acceptable.
Source: Drug Industry Daily